Literature DB >> 3262463

Serum HIV antigen and anti-P24-antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets.

J M Andrieu1, D Eme, A Venet, C Audroin, J M Tourani, M Stern, D Israel-Biet, K Beldjord, F Driss, P Even.   

Abstract

Serum HIV (P24) antigen (Ag) measured by an antigen capture ELISA (Abbott) and anti-P24-antibodies (Abs) measured by a competitive ELISA (Abbott) and by Western Blot (Dupont de Nemours) analysis were correlated with lymphocyte subsets (CD4 and CD8) in 174 HIV seropositive patients without AIDS (non-AIDS) and 26 with AIDS. In the non-AIDS group, 27% of the patients were anti-P24-Ab negative and 21% were Ag positive while in the AIDS group these figures were 62% and 54% respectively (P less than 0.001). Overall, a significant correlation exists between the Ab-Ag profile and the CD4 cell count: the percentage of patients with anti-P24-Ab positive and Ag negative decreases from 90% for patients with more than 900 CD4 cells/microliter to 21% for patients with 100 and less CD4 cells/microliter; on the contrary, the percentage of patients with anti-P24-Ab negative and Ag positive increases from 0% over 800 CD4 cells to 53% under 100 CD4 cells/microliter. A weak correlation may also exist with the CD8 cell count. The subgroup of patients with 1,000 or more CD8 cells/microliter have a higher (but not significant) percentage of subjects with Ag positive and anti-P24-Ab negative than the subgroup with less than 1,000 CD8 cells/microliter. A short-term longitudinal study (mean follow-up: 1 year) was performed on 80 non-AIDS subjects: 77% (10/13) of those who had a CD4 cell decrease (greater than 30%) were initially Ag positive, while only 21% (14/67) of those without a decrease were Ag positive at the beginning (P less than 0.1). Although the relative weight and individual predictive value of each of these parameters need to be classified, they are probably the best biological markers currently available for monitoring clinical trials with experimental drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262463      PMCID: PMC1541456     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

2.  AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications.

Authors:  J M Andrieu; P Even; A Venet
Journal:  AIDS Res       Date:  1986

3.  AIDS vaccine predictions.

Authors:  F Barin
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

4.  Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection.

Authors:  J Goudsmit; J M Lange; D A Paul; G J Dawson
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

5.  Prospects for the control of AIDS by immunizing seropositive individuals.

Authors:  J Salk
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

6.  HIV antigen testing.

Authors:  C Kenny; J Parkin; G Underhill; N Shah; B Burnell; E Osborne; D J Jeffries
Journal:  Lancet       Date:  1987-03-07       Impact factor: 79.321

7.  Decline of antibody reactivity to HIV core protein secondary to increased production of HIV antigen.

Authors:  J Lange; J Goudsmit
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

8.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

Authors:  F Barin; M F McLane; J S Allan; T H Lee; J E Groopman; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

9.  Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS).

Authors:  R J Biggar; M Melbye; P Ebbesen; S Alexander; J O Nielsen; P Sarin; V Faber
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-12

10.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more
  8 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

2.  Actuarial rate of clinical and biological progression in a cohort of 250 HIV-1-seropositive subjects. Laennec HIV Study Group.

Authors:  A Venet; J M Tourani; K Beldjord; D Eme; P Even; J M Andrieu
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

3.  Immunosuppression by pulmonary surfactant: mechanisms of action.

Authors:  M L Wilsher; D J Parker; P L Haslam
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

4.  Evaluation of two enzyme immunoassays for detection of human immunodeficiency virus antigen in African and European sera.

Authors:  G Vercauteren; P Piot; M Vandenbruaene; G van der Groen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

5.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 6.  Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation.

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  Dichotomy of two CD8+ lymphocyte subsets in HIV infection. Depletion of CD8+ CD3- and expansion of CD8+ CD3+ subsets: consequence on the CD4/CD8 ratio.

Authors:  I Mansour; C Doinel; P Rouger
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

8.  High levels of anti-Nef antibodies may prevent AIDS disease progression in vertically HIV-1-infected infants.

Authors:  Guillermo Corró; Cintia Milena Crudeli; Carlos Alberto Rocco; Silvia Alejandra Marino; Luisa Sen
Journal:  J Int AIDS Soc       Date:  2014-02-14       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.